Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, shares why the MATTERHORN trial was selected for the plenary session and how its findings build on past studies to advance perioperative care in G/GEJ cancer.

She highlights the study’s global scope, strong safety profile, and promising efficacy signals—including improved event-free survival—and previews upcoming biomarker analyses that could personalize treatment even further.